Business & regional news

Month Year

Email alerts

Sep 21, 2022

Medtronic is the first and only company to receive FDA indication for bifurcation percutaneous coronary intervention with a drug-eluting stent

Bifurcation using Onyx Frontier DES Medtronic announced today that it has received Food and Drug Administration (FDA) approval for the treatment of non-left main bifurcation lesions utilizing the...
- Coronary and Renal Denervation
Sep 20, 2022

Medtronic receives CE mark for the first balloon expandable covered stent indicated for chimney endovascular aneurysm repair (ChEVAR)

Medtronic announced today that it recently received CE mark for its Radiant™ balloon-expandable covered stent, the first and currently only covered stent indicated for use in ChEVAR with the...
- Structural Heart and Aortic
Sep 18, 2022

MEDTRONIC UNVEILS NEW DATA FROM INVESTIGATIONAL INTREPID™ TRANSCATHETER MITRAL VALVE REPLACEMENT PROGRAM TO EXPAND TREATMENT OPTIONS FOR SEVERE MITRAL REGURGITATION

TCT 2022: Late-breaking data from Intrepid™ Pilot Study 3-year follow-up & 1-year follow-up from Transfemoral EFS study demonstrate promising valve performance Medtronic today announced new data...
- Structural Heart and Aortic
Sep 16, 2022

FIRST-EVER COMPARISON OF MICROCT AND HISTOLOGY IN SELF-EXPANDING TRANSCATHETER AORTIC VALVE REPLACEMENT PATIENTS WITH HYPO-ATTENUATED LEAFLET THICKENING

TCT 2022: Pathological Findings Confirm Importance of Early Detection and Treatment of Thrombus on Valve Leaflets Medtronic today announced findings from its Pathological Study of Hypo-Attenuated...
- Structural Heart and Aortic
Sep 16, 2022

MEDTRONIC ANNOUNCES FULL MARKET LAUNCH IN U.S. OF EVOLUT™ FX NEXT-GEN TAVR SYSTEM FOR TREATMENT OF SYMPTOMATIC SEVERE AORTIC STENOSIS

TCT 2022: Medtronic Unveils Latest Transcatheter Aortic Valve Replacement Data in Late-Breaking Clinical Science and Presentations
- Structural Heart and Aortic

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa